Europe — EMA
Olmesartan Medoxomil And Amlodipine Clydesdale Pharma (Olmesartan Medoxomil, Amlodipine)
GNH USA supplies Olmesartan Medoxomil And Amlodipine Clydesdale Pharma (Olmesartan/Amlodoxy), a hypertension drug class for high blood pressure management.
Request sourcing
What is Olmesartan Medoxomil, Amlodipine?
Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil And Amlodipine Clydesdale Pharma, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond what a single agent can provide.
GNH USA supplies Olmesartan Medoxomil And Amlodipine Clydesdale Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Olmesartan Medoxomil, Amlodipine used for?
Olmesartan medoxomil and amlodipine is indicated for the management of high blood pressure within the renin‑angiotensin‑aldosterone system and calcium‑channel pathways. - Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient. - Isolated systolic hypertension in the elderly: improves systolic control while maintaining tolerability. - Hypertensive patients with concomitant peripheral edema from calcium‑channel blockers: amlodipine’s vasodilatory effect is balanced by olmesartan’s arterial relaxation.
What are the side effects of Olmesartan Medoxomil, Amlodipine?
Both ingredients are generally well tolerated, but adverse reactions can occur.
Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness: especially after the first dose. - Flushing: transient warmth sensation. - Fatigue: general tiredness. - Nausea: occasional upset stomach.
Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips or throat. - Severe hypotension: marked drop in blood pressure causing faintness. - Hepatic dysfunction: abnormal liver enzymes. - Hyperkalemia: elevated potassium levels. - Renal impairment: worsening kidney function. - Myocardial infarction: rare but reported in susceptible patients.
What precautions apply to Olmesartan Medoxomil, Amlodipine?
Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Renal function: evaluate creatinine clearance and adjust if necessary. - Hepatic function: check liver enzymes in patients with liver disease. - Electrolytes: monitor potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy: avoid use; teratogenic risk is associated with angiotensin‑II blockade. - Elderly patients: start at lower dose and titrate cautiously. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.
What does Olmesartan Medoxomil, Amlodipine interact with?
Olmesartan medoxomil and amlodipine may interact with several drug classes; clinicians should review concomitant medications.
Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of severe hypotension and renal failure. - Potassium‑sparing diuretics or supplements: may cause hyper‑kalemia.
Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function. - CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce amlodipine exposure. - Lithium: may increase serum lithium concentrations. - Alcohol: additive hypotensive effect, monitor blood pressure.
